Company: MIRA
Filing Date: 2025-09-30
Form Type: 8-K
Source: 0001493152-25-016168
Chunk: 1

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-09-30
Form: 8-K
Item: Item 2.01
Chunk 1
---
Item
2.01. Completion of Acquisition or Disposition of Assets

The
information contained in Item 1.01 above is incorporated herein.

Item 3.02.
Unregistered Sales of Equity Securities.

The
information contained in Item 1.01 above is incorporated herein. The Shares were issued in reliance upon the exemption contained in Section
4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder.

8.01
Other Events

On
April 8, 2025, the Company received a written notification from the Listing Qualifications Department (the “ Staff”) of The
Nasdaq Stock Market, LLC (“ Nasdaq”) notifying the Company that it did not comply with Listing Rule 5550(b)(1) (the “ Rule”),
which requires a minimum $2,500,000 stockholders’ equity. On May 7, 2025, the Company responded to this notification with a submission
(the “ Submission”). Based on Nasdaq’s review of the Submission, the Staff determined to grant the Company an extension
until October 6, 2025 to regain compliance with the Rule.

Following
sales of the Company’s stock through multiple at-the-market offering transactions, as well as the closing of the Merger, as of
the date of this report, the Company believes it has regained compliance with the Rule. The Company understands that Nasdaq will continue
to monitor the Company’s ongoing compliance with the Rule and, if at the time of its next periodic report the Company does not
evidence compliance, that it may be subject to delisting.

Item
9.01. Financial Statements and Exhibits

(d)
Exhibits.

  Exhibit      Exhibit                                                                                                                                     
      No.      Description                                                                                                                                 
     10.1      Merger Agreement, dated September 29, 2025, between MIRA Pharmaceuticals, Inc., MIRAPHARM Acquisition, Inc. and SKNY Pharmaceuticals, Inc.  
 ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
      104      Cover                                                                                                                                       

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                          MIRA                                         
  Dated:                  By:                       /s/                
                          Name:                     Erez